Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05483491 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05483491 · ClinicalTrials.gov record · last posted 2026-08-25

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Name: KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer — clinical trial record (NCT05483491)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChristian Hinrichs

Started2022-09-26

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.

Protocol amendment history 2 changes detected by DataLookout

2026-08-26

Primary completion pushed: 2026-09-01 → 2028-09-01

2026-08-26

Completion pushed: 2028-12-31 → 2030-12-31

Trial Details

NCT Number	NCT05483491
Lead Sponsor	Christian Hinrichs Collaborators: National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Conditions	Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Enrollment	30 participants
Start Date	2022-09-26
Primary Completion	2028-09-01 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-25